Clinical efficacy of atezolizumab plus bevacizumab in the first-line treatment of advanced hepatocellular carcinoma
10.3760/cma.j.cn115610-20211112-00563
- VernacularTitle:阿替利珠单克隆抗体联合贝伐珠单克隆抗体在晚期肝细胞癌一线治疗中的临床疗效
- Author:
Yi LU
1
;
Junwei LIU
;
Guoliang SHEN
;
Junfa CHEN
;
Tingyang HU
;
Haijun HUANG
;
Ran TAO
;
Chengwu ZHANG
Author Information
1. 浙江省人民医院（杭州医学院附属人民医院）肝胆胰外科，杭州 310014
- Keywords:
Liver neoplasms;
Advanced;
Atezolizumab;
Bevacizumab;
Clinical efficacy
- From:
Chinese Journal of Digestive Surgery
2021;20(S2):25-28
- CountryChina
- Language:Chinese
-
Abstract:
Primary hepatic carcinoma has ranked as the sixth most commonly diagnosed cancer and the third leading cause of cancer death. China shares about 50% of new liver cancer cases, including 80% of hepatic carcinoma. Non-surgical therapy continues to make breakthroughs. The authors report a case of hepatic carcinoma with intrahepatic metastasis and tumor thrombus in the left portal vein, which has achieved continious partial response after the treatment of atezoli-zumab combined with bevacizumab, without adverse reactions such as liver and kidney function damage. The life quality of the patient was improved, showing safety and efficacy of the treatment.
